XEFO 8 MG
Central Nervous System-Analgesics; Antipyretics
= Additional active ingredients
PRESENTATION AND DOSSAGE
TABS: 20 X 8 mg
Short term treatment of moderate pain (after dental surgery), pain associated with acute lumbo-sciatica. Symptomatic treatment of pain and inflammation in osteo/rheumatoid arthritis.
Allergy to lornoxicam, or any excipients of the product. Hypersensitivity (symptoms like asthma, rhinitis, angioedema or urticaria) or to other NSAIDs, including acetylsalicylic acid. GI bleeding, cerebrovascular bleeding or other bleeding disorders. Active peptic ulceration or history of recurrent peptic ulceration. Severe liver impairment. Severe renal impairment (serum creatinine > 700 mcgmol/L). Severe thrombocytopenia, severe heart insufficiency. Elderly patients (>65 years) and weighing less than 50 kg and undergoing acute surgery. Pregnancy and lactation. Patients under 18 years of age.
History of GI ulceration and bleeding. Renal impairment. Blood coagulation disorders. Liver diseases (e.g. liver cirrhosis). Long term treatment (longer than 3 months). Elderly patients (65 years or above). Hypertension and/or obesity. Monitoring of blood and renal function is recommended.
GI ulcerations with intestinal perforation, which may be severe. Duodenal ulcers, hematemesis and melaena. Possible onset of severe skin reactions and serious life threatening hypersensitivity reactions. In rare cases: Intersticial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome. Disturbances of blood count, blood dyscrasia, leucocytopenia.
Anticoagulants or platelet aggregation inhibitors, sulphonylureas, other non steroidal anti-inflammatory drugs. Diuretics, ACE inhibitors, lithium, methotrexate and cyclosporine, cimetidine, digoxin, tranylcypromine and rifampicin.
MANUFACTURER & DISTRIBUTER:
Manufacturer: Nycomed Pharma
License Holder: CTS Chemical Ind. Ltd.